Navigation Links
Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management

WEST TRENTON, N.J., July 10 /PRNewswire/ -- Archi-Tech Systems, a leading provider of pharmaceutical data analytics and reporting solutions, today announced DART(TM) PromoTrack, a new solution custom-designed to rapidly measure the impact of pharmaceutical marketing campaigns and prescriber promotions. Archi-Tech has tailored its proven DART technology to meet the specific needs of pharmaceutical marketers, seamlessly integrating disparate promotional campaign and Rx sales data to facilitate on-the-fly analytics and reporting. For the first time, marketers have endless configurations of critical data at their fingertips to better monitor advertising, sampling, educational seminars, and other promotional tools for compliance and effectiveness.

"Pharmaceutical marketers are challenged to run successful campaigns under tight budgets and intense regulatory scrutiny. But with mountains of data to sift through, they often cannot properly measure the results of their promotions to adapt their strategies accordingly," said Prashant Kohli, Vice President of Sales and Marketing for Archi-Tech. "DART PromoTrack provides faster, more accurate insight into specific campaigns to improve planning, streamline targeting, enhance messaging, ensure compliance -- and ultimately maximize marketing dollars spent."

Built on the proven DART solution, already widely used by the pharmaceutical industry for instant, in-depth analytics and reporting on sales, marketing, and managed care data, DART PromoTrack offers unmatched flexibility to analyze and report on any configuration of data across the full scope of prescriber metrics and activity. This brings together Rx, call/sample, demographic, campaign, promotional, and other detail in a single view that encompasses millions of physicians and multiple markets and specialties. Pharmaceutical marketing teams can run multi-dimensional searches in seconds, conduct ad-hoc analyses, and generate instant reports on a wide range of datasets and parameters, regardless of volume or complexity. This yields actionable information to more effectively track marketing initiatives, manage control group activity, monitor trends, review results against actual performance, and more.

About Archi-Tech

Archi-Tech Systems is a leading provider of solutions for instant analytics and powerful reporting for pharmaceutical sales, marketing, and managed care departments. Balancing deep data expertise with advanced technology solutions and a unique service model, Archi-Tech addresses the full scope of a company's data analysis and reporting needs, no matter how simple or complex. The company's solutions offer unmatched speed and compression for any type of data, from any source, regardless of volume or complexity. In addition, the Archi-Tech team offers more than 100 years of combined experience with industry leading data vendors, and direct pharmaceutical client service experience. This translates to a unique understanding of the data, and exactly how our clients need to use it. For more information, visit

SOURCE Archi-Tech Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
2. Par Pharmaceutical to Launch meclizine HCL Tablets
3. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
4. Lilly to Acquire SGX Pharmaceuticals
5. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
6. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
9. Transcept Pharmaceuticals Appoints Key Senior Executives
10. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
11. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), ... MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing ... AMA members have embraced this type of racing and several new model aviation pilots ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
Breaking Biology Technology:
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
(Date:10/22/2015)... Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), a ... for its third quarter ended September 30, 2015.  ... of 2015 was $4.0 million, a decrease of 33% compared to ... the third quarter of 2015 was $2.2 million, or $0.10 per ... share, in the same period a year ago.  ...
Breaking Biology News(10 mins):